A phase II trial to evaluate the rate of immune response using idiotype immunotherapies produced by molecular biological means for treatment of indolent B cell lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs GTOP 99 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 13 Jan 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2005 New trial record.